Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
17.08.2015
Veloxis Pharmaceuticals Envarsus® XR Granted Orphan Drug Status by U.S. Food and Drug Administration for Kidney Transplant Rejection Prophylaxis
Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that Envarsus® XR was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Envarsus® XR received marketing authorization from the FDA on July 10, 2015.
Dato
10.08.2015
Vtesse, Inc. Announces Preliminary Data from Ongoing Phase 1 Study of VTS-270 for Treatment of Niemann-Pick Disease Type C
Post-Hoc Analyses of Data Show Preliminary Evidence of Overall Disease Stabilization with Improvement in Several Disease Domains
Dato
03.08.2015
Ziarco Appoints Mike Grey as Executive Chairman of Board of Directors
CANTERBURY, UK, 20 JULY, 2015 -- Ziarco Group Ltd., a biopharmaceutical company focusing on inflammatory skin diseases, today announced the appointment of Mike Grey as Executive Chairman of its Board of Directors, effective immediately. Mr. Grey first joined the Company’s board as an independent director in December 2014. 
Dato
26.06.2015
Envarsus® XR Demonstrates Differentiated Pharmacokinetic Profile Compared to Twice-Daily Prograf® or Once-Daily Astagraf XL® in Stable Kidney Transplant Patients
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced top-line results of the ASTCOFF study, A STeady-state Pharmacokinetic COmparison Of all FK-506 Formulations, demonstrating that once-daily Envarsus® XR (tacrolimus extended-release tablets), an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, achieved differentiated pharmacokinetics (PK) when compared to twice-daily tacrolimus (Prograf®) or a once-daily tacrolimus product (Astagraf XL®). 
Dato
24.06.2015
CERAMENT™ STUDY RECOGNIZED AT THE 16TH EFORT CONGRESS IN PRAGUE
Lund, Sweden, (PRNEWSWIRE) June 23, 2015 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, is pleased to announce that a recent study entitled, A Biphasic Apatite/Sulphate Bone Substitute, CERAMENT™ Induces Bone In a Skeletal Muscle Cell Line, was awarded with the EFORT (European Federation of National Associations of Orthopaedics and Traumatology) Free Paper Award at the 16th EFORT Congress in Prague.  This paper was one of only three to receive an award and was based on a study conducted by a group of renowned scientific and clinical collaborators from Sweden, Denmark, the United Kingdom and India.  The study demonstrates that CERAMENT™ is bioactive with the potential to lead to accelerated bone regeneration possibly without having to use artificial anabolic agents. 
Dato
16.06.2015
Vtesse, Inc. Expands Scientific Advisory Board, Fills Key Patient Advocacy Position to Prepare for Further Clinical Development of VTS-270 in Niemann-Pick Disease Type C (NPC)
Gaithersburg, MD, June 15, 2015 – Vtesse, Inc.,  a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases with great unmet need, announced today the expansion of its Scientific Advisory Board (SAB) and the filling of a key staff position in patient advocacy.  
Dato
10.06.2015
Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis
CANTERBURY, UK, 10 JUNE, 2015 -- Ziarco Group Ltd., a biopharmaceutical company focusing on inflammatory skin diseases, today announced that it has dosed the first patient in its Phase 2a proof-of-concept clinical trial of ZPL-389 in patients with moderate to severe atopic dermatitis at MAC Clinical Research in Manchester, UK. ZPL-389 is the Company’s novel, once-daily, oral histamine H4 receptor antagonist for the treatment of inflammatory skin diseases, including atopic dermatitis and psoriasis. 
Dato
10.06.2015
Ziarco Announces Appointment of Dr. Pablo Jimenez as Chief Medical Officer
CANTERBURY, UK, 8 JUNE, 2015 -- Ziarco Group Ltd., a clinical-stage biopharmaceutical company focusing on inflammatory skin diseases, today announced the appointment of Pablo Jimenez, M.D., as Chief Medical Officer, effective immediately. Dr. Jimenez will oversee the clinical development of Ziarco’s programs targeting conditions such as atopic dermatitis and psoriasis.
Dato
08.06.2015
Spero Completes $30 Million Financing

Expands focus on gram-negative bacteria by adding Potentiator program to pipeline of novel antibiotic compounds.

CAMBRIDGE, Mass.– June 8, 2015 –  Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced that the company secured $30M million in a Series A financing.  Lundbeckfond Ventures led the round as a new investor with participation from additional new investors Merck Research Ventures and The Kraft Group. All existing investors participated including Atlas Venture, SR One, and Partners Innovation Fund.  The company also expanded its pipeline of novel anti-infectives through the addition of a Potentiator program targeting Gram-negative infections.  Spero plans to use the proceeds from this financing to advance the potentiator franchise into the clinic by 2016, progress its anti-virulence program in partnership with Roche through the submission of an Investigational New Drug (IND) application, and develop additional programs in its pipeline focused on unmet medical needs in bacterial infections.  

Dato
27.05.2015
CERAMENT™|G SHOWN TO INCREASE BONE FORMATION AND DECREASE INFECTION
Pivotal Rat Study Presented at 2015 Orthopedic Research Society Annual Meeting  

Lund, Sweden, (PRNEWSWIRE) May 27, 2015 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced results from a pivotal pre-clinical study of CERAMENT™|G as presented at the 2015 Orthopedic Research Society (ORS) Annual Meeting.  The study assessed the efficacy and safety of CERAMENT™|G, the first injectable gentamicin eluting bone substitute, in the completeness of bone healing after surgery and in the eradication of chronic infection.  Study results demonstrated that CERAMENT™|G increased new bone growth and decreased the rate of infection as compared to treatment without a bone filler and treatment with CERAMENT™|BONE VOIDE FILLER without gentamicin.   

Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste